Doctor or nurse is holding the Cancer vaccine and syringe with her blue glove.
It is a known fact that cancer is one of the most dangerous diseases, claiming hundreds of thousands of lives every year across the globe. The latest development suggests that Russia may have found a cure for cancer, as clinical trials have shown 100% effectiveness.
The Enteromix cancer vaccine, developed in Russia, has demonstrated complete efficiency in trials and is now set for mass clinical use.
FMBD head Veronica Skvortsova announced that the mRNA-based vaccine successfully passed preclinical trials, proving its safety and high effectiveness. The vaccine showed remarkable results in shrinking tumors, slowing their growth, and was also found safe for repeated use.
What makes this vaccine unique is that it will be customized for each patient, tailored to their individual RNA. The first version will be used to treat colorectal cancer, while another is being developed for glioblastoma.
Similar to the Covid vaccine, this cancer vaccine will help the body identify cancer cells and eliminate them effectively. Unlike chemotherapy and radiation, this vaccine reportedly comes with no side effects.
The vaccine was tested on 48 individuals and showed excellent results.
The best part? It is expected to be made available completely free of charge, meaning patients will not have to pay anything to receive it.
This post was last modified on 8 September 2025 10:54 pm
US President Donald Trump has made a major announcement regarding American financial support to Israel.…
The kind of numbers that were witnessed in the 2019 Andhra Pradesh election were truly…
Andhra Pradesh local body elections have completed a crucial procedure today with municipal elecfion counting…
Jagan Reacts Sorely To Municipal Poll Disaster, Sings Same Song! Immediately after the 2024 Andhra…
The Telangana High Court has extended its stay on orders seeking HYDRAA chief AV Ranganath’s…
Maturity and humanity at the two crucial aspects that are expected from a successful politician,…